U.S. Scrial No.: 09/923,270 Atty. Docket No.: 34021/US

<u>AMENDMENTS</u>

IN THE CLAIMS:

Please amend the claims as follows:

1-12. (Cancelled)

- 13. (Presently amended) [A] An adeno-associated virus (AAV) nucleic acid comprising an AAV helper virus sequence for developing AAV viral particles, wherein said [nucleic acid] AAV helper virus sequence comprises the complete adenovirus 5 sequence with exception of the El region.
- 14. (Presently amended) [A] An adeno-associated virus (AAV) nucleic acid comprising an AAV helper virus sequence for developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248.
- 15. (Presently amended) [A] An adeno-associated virus (AAV) nucleic acid comprising an AAV helper virus sequence for developing AAV viral particles, wherein said nucleic acid comprises the complete adenovirus 5 sequence with exception of the L1 and E1 region.
- 16. (Presently amended) [A] An adeno-associated virus (AAV) nucleic acid comprising an AAV helper virus sequence for developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Z likulturen under DSMZ 11817.

1129208_1

U.S. Serial No.: 09/923,270 Atty. Docket No.: 34021/US

- 17. (Previously amended) A composition comprising the nucleic acid of Claim13, 14, 15, or 16, and an rAAV vector.
 - 18. (Previously added) The composition of Claim 17, further comprising a cell.
- 19. (Previously added) The composition of Claim 18, wherein said cell is a mammalian cell.
- 20. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to [a] an AAV nucleic acid comprising an AAV helper virus sequence for developing AAV viral particles, wherein said [nucleic acid] AAV helper virus sequence comprises the complete adenovirus 5 sequence with exception of the E1 region;
 - b) inducing said cells to develop rAAV viral particles; and
 - c) isolating said rAAV viral particles.
- 21. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

exposing cells to [a] an AAV nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248;

- b) inducing said cells to develop rAAV viral particles; and
- c) isolating said rAAV viral particles.

U.S. Serial No.: 09/923,270 Auy. Docket No.: 34021/US

- 22. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to [a] an AAV nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said [nucleic acid] AAV helper virus sequence comprises the complete adenovirus 5 sequence with exception of the L1 and the E1 region;
 - b) inducing said cells to develop rAAV viral particles; and
 - c) isolating said rAAV viral particles.
- 23. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to a nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817;
 - b) inducing said cells to develop rAAV viral particles; and
 - c) isolating said rAAV viral particles.
- 24. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to a composition comprising (1) an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of the E1 region, and (2) an rAAV vector;
 - b) inducing said cells to develop rAAV viral particles; and
 - c) isolating said tAAV viral particl s.

U.S. Scrial No.: 09/923,270 Atty. Docket No.: 34021/US

- 25. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to a composition comprising (1) an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248;
 - b) inducing said cells to develop rAAV viral particles; and
 - c) isolating said rAAV viral particles.
- 26. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to a composition comprising (1) an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of the L1 and the E1 region;
 - b) inducing said cells to develop rAAV viral particles; and
 - c) isolating said rAAV vital particles.
- 27. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to a composition comprising (1) an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817;
 - b) inducing said cells to develop rAAV viral particles; and
 - c) isolating said rAAV viral particles.